etira
  • Home
  • Our Company
  • Our Science
  • Clinical Trial
  • Our Pipeline
  • Our Team
  • News
  • Contact
  • Menu Menu
  • LinkedIn
  • Home
  • Our Company
  • Our Science
  • Clinical Trial
  • Our Pipeline
  • Our Team
  • News
  • Contact

Intro - Slide 1 Preclinical Phase 2 Optimization Discovery Phase 1 ERX-315 Metastatic Cancers Ovarian Cancer ERX-208 ERX-41 Pancreatic Cancer ER+MT MBC TX-542 Pipeline This page summarizes Etira’s investigational small-molecule programs and current development stages. Language is non-promotional; safety and efficacy have not been established.

ERX-315 and other Etira programs are investigational; safety and efficacy have not been established.

 

etira logo

 

Where to find us

Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247

Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247

Scroll to top
Inclusion criteria:
  • Patients must be at least 18 years of age at the time of signing the informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
  • Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Adequate baseline organ function and hematologic function
  • Life expectancy >3 months
Exclusion criteria
  • Systemic anti-cancer therapy within 4 weeks of first dose of study drug
  • Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
  • Uncontrolled intercurrent illnesses
  • Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.